PT - JOURNAL ARTICLE AU - Dudukina, Elena AU - Horváth-Puhó, Erzsébet AU - Sørensen, Henrik Toft AU - Ehrenstein, Vera TI - Association between having a pregnancy complicated by vaginal bleeding and risk of cancer AID - 10.1101/2021.12.29.21268235 DP - 2022 Jan 01 TA - medRxiv PG - 2021.12.29.21268235 4099 - http://medrxiv.org/content/early/2022/11/28/2021.12.29.21268235.short 4100 - http://medrxiv.org/content/early/2022/11/28/2021.12.29.21268235.full AB - Background A full-term pregnancy is associated with a lower cancer risk. The risk of cancer in women with vaginal bleeding in pregnancy is unknown.Methods We conducted a registry-based cohort study (1995-2017) in Denmark. We included pregnancies (n=37 082) affected by vaginal bleeding (VB) within 20 gestational weeks among 35 514 women, VB-unaffected pregnancies (n=1 363 614) among 783 314 women, pregnancies ending in a termination (n=324 328) among 239 638 women or miscarriage (n=137 104) among 121 353 women. We computed absolute risk of cancer and hazard ratios (HR) with 95% confidence intervals (CI) adjusted for age, calendar year, morbidity, and socioeconomic factors using Cox proportional hazards regression.Results At the end of the 24-year follow-up, there were 1 320 events among VB-affected cohort, 40 420 events among VB-unaffected cohort, 10 300 events among termination cohort, and 4 790 events among miscarriage cohort. The HR for any cancer was 1.03 (95% CI: 0.97-1.08) when comparing VB-affected vs VB-unaffected pregnancies, 1.03 (95% CI: 0.97-1.09) vs terminations, and 0.90 (95% CI: 0.84-0.95) vs miscarriages. Similar results were obtained for site-specific cancers.Conclusions We found no strong evidence for an association between vaginal bleeding in pregnancy and an increased risk of cancer.Competing Interest StatementThe authors have declared no competing interest.Funding StatementDepartment of Clinical Epidemiology, Aarhus University, which is partaking in studies with institutional funding from regulators and pharmaceutical companies, given as research grants to and administered by Aarhus University. None of these projects is related to the current study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No patient consent or ethical approval is required for registry-based research according to Danish legislation. This study was reported to the Danish Data Protection Agency through registration at Aarhus University (record number: AU-2016-051-000001, sequential number 605).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is not available for sharing to protect the identity of participants according to Danish legislation.